Wave Life Sciences (WVE) Operating Margin (2015 - 2026)
Wave Life Sciences' (WVE) quarterly Operating Margin came in at 3248.33% in Q2 2026, down 264183.0% YoY from N/an in Q2 2025, and down 3869.44% on a QoQ basis from 81.83% in Q1 2026.
Wave Life Sciences (WVE) Operating Margin (2015 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of Operating Margin data on file, last reported at 3248.33% in Q2 2026.
- Quarterly Operating Margin fell 264183.0% year-over-year to 3248.33% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 373.2% (down 8678.0% YoY) and the FY2025 annual result came in at 504.09%, down 40215.0% from the prior year.
- Operating Margin eased to 3248.33% in Q2 2026, from 81.83% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 9.03% in Q3 2023 to a low of 13648.77% in Q3 2022.
- A 5-year average of 2565.21% and a median of 408.83% in 2025 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin sank 1362789 bps — and 2023, when it surged 1365780 bps.
- Tracing WVE's Operating Margin over 5 years: stood at 3515.98% in 2022, then jumped by 98 bps to 64.3% in 2023, then slumped by 176 bps to 177.72% in 2024, then plunged by 241 bps to 606.49% in 2025, then plunged by 436 bps to 3248.33% in 2026.
- The last three Operating Margin figures came in at 3248.33% (Q2 2026), 81.83% (Q1 2026), and 606.49% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | -3,248.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,248.33% |
| Mar 31, 2026 | -81.83% |
| Jun 30, 2025 | -606.49% |
| Mar 31, 2025 | -542.82% |
| Jun 30, 2024 | -177.72% |
| Mar 31, 2024 | -274.83% |
| Dec 31, 2023 | -64.30% |
| Sep 30, 2023 | 9.03% |
| Jun 30, 2023 | -106.18% |
| Mar 31, 2023 | -234.24% |
| Dec 31, 2022 | -3,515.98% |
| Sep 30, 2022 | -13,648.77% |
| Jun 30, 2022 | -11,243.73% |
| Mar 31, 2022 | -2,176.80% |
| Dec 31, 2021 | -2,045.89% |
| Sep 30, 2021 | -20.89% |
| Jun 30, 2021 | -1,434.73% |
| Dec 31, 2020 | -321.15% |
| Sep 30, 2020 | -997.54% |
| Jun 30, 2020 | -1,277.04% |